HR Execs on the Move

Source Medical Solutions

www.sourcemed.net

 
SourceMedical is the largest provider of ASC software and therapy software in addition to billing services for ambulatory surgery centers, specialty hospitals, and rehabilitation clinics nationwide measured by both experience and size of customer base. With 30 years of real-world experience, more than 5,200 customers, and the confidence of more than 250 consultants and management companies, SourceMedical offers the broadest range of solutions and enhancements available to the industry. SourceMedical products help ambulatory surgery centers, rehabilitation clinics, and specialty hospitals address vitally important performance issues so they can focus on quality patient care. Our mission is to provide the highest ...
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million
  • www.sourcemed.net
  • 100 Grandview Pl Ste 400
    Birmingham, AL USA 35243
  • Phone: 866.245.8093

Executives

Name Title Contact Details

Similar Companies

Exos

EXOS is a leader in the field of human performance, a category it created more than 15 years ago. Today, EXOS employs more than 3,500 people in over 400 locations worldwide. With award-winning facilities, technology, and services, EXOS helps people take control of their health and performance so they can achieve what matters most to them. EXOS is trusted by hundreds of clients, including one-quarter of Fortune 100 companies, world champions in sports, and leaders in health care, military, and community organizations.

iCarbonX

iCarbonX is building a digital life ecosystem by combining consumer life data, the Internet and artificial intelligence.

Betz Nursing Home

Betz Nursing Home is a Auburn, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hughes BioPharma Advisers

Hughes BioPharma Advisers is a Darien, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.